Zurich, Switzerland, May 15, 2006: OphthalmoPharma Ltd. (OPPH), a pharmaceutical company specializing in the development of ophthalmology products, announces a CHF 5.75 Mio capital increase with private and institutional investors. The funding will be utilized to bring the SOLO intra-ocular lens injector through the CE Mark registration process, to take OPPH’s two lead products – cyclodextrin solubilized Cyclosporin A and cyclodextrin solubilized triamcinolone – through Phase I clinical trials, and to acquire and develop other innovative products. CEO Dr. Randall Gatz states, “We are delighted to have closed this round of funding with a select group of investors. Our product pipeline addresses major unmet medical needs in ophthalmology.”
